Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802182 | 1.00 | YTHDC1 (0.44) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL19328314 | 0.86 | YTHDC1 (0.47) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL17802181 | 0.86 | YTHDC1 (0.47) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL15740441 | 0.83 | YTHDC1 (0.49) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL8894747 | 0.83 | YTHDC1 (0.49) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL12761893 | 0.82 | YTHDC1 (0.46) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL25486005 | 0.82 | YTHDC1 (0.47) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL26087088 | 0.82 | YTHDC1 (0.47) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| Hydrochloric Acid SCHEMBL8906626 | 0.82 | YTHDC1 (0.48) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| Hydrochloric Acid SCHEMBL17802162 | 0.82 | YTHDC1 (0.48) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| EP-3227275-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| WO-2016087975-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087975-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | CD38, NQO1, NADK | YTHDC1 4564/4885SLC6A2 2463/4885SLC6A4 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.